Skip to content

Integra LifeSciences IART Deferred compensation plan assets

Deferred compensation plan assets at other companies

Henry Schein logo
Henry ScheinHSIC
Envista Holdings Corporation logo
Envista Holdings CorporationNVST

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:DeferredCompensationPlanAssets.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's deferred compensation plan assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's deferred compensation plan assets?
Integra LifeSciences (IART) reported deferred compensation plan assets of $7.3M in Q1 2026.
How has Integra LifeSciences's deferred compensation plan assets changed year-over-year?
Integra LifeSciences's deferred compensation plan assets increased by 7.4% year-over-year, from $6.8M to $7.3M.
What is the long-term trend for Integra LifeSciences's deferred compensation plan assets?
Over 5 years (2020 to 2025), Integra LifeSciences's deferred compensation plan assets has grown at a 31.6% compound annual growth rate (CAGR), from $2M to $7.9M.